Summit Therapeutics (SMMT) Gross Margin (2017 - 2020)
Summit Therapeutics' (SMMT) quarterly Gross Margin came in at 2345.34% in Q1 2020, down 71574.0% YoY from N/an in Q2 2019, and down 3001.93% on a QoQ basis from 80.82% in Q4 2019.
Summit Therapeutics (SMMT) Gross Margin (2017 - 2020) Analysis & Trends
Summit Therapeutics (SMMT) has 4 years of Gross Margin data on file, last reported at 2345.34% in Q1 2020.
- Quarterly Gross Margin fell 71574.0% year-over-year to 2345.34% in Q1 2020, while the trailing twelve-month figure through Mar 2020 was 128.56% (up 12280.0% YoY) and the FY2019 annual result came in at 4383.58%, changed N/A from the prior year.
- Gross Margin declined to 2345.34% in Q1 2020, from 80.82% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 80.82% in Q4 2019 to a low of 6205.65% in Q4 2019.
- A 4-year average of 1452.01% and a median of 328.43% in 2017 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2018 — Gross Margin jumped 16215 bps — and 2019, when it plunged 495261 bps.
- Tracing SMMT's Gross Margin over 4 years: stood at 197.34% in 2017, then sank by 602 bps to 1385.04% in 2018, then soared by 106 bps to 80.82% in 2019, then sank by 3002 bps to 2345.34% in 2020.
- The last three Gross Margin figures came in at 2345.34% (Q1 2020), 80.82% (Q4 2019), and 6205.65% (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -2,345.34% |
| Dec 31, 2019 | 80.82% |
| Oct 31, 2019 | -6,205.65% |
| Jul 31, 2019 | -4,888.10% |
| Mar 31, 2019 | -1,629.60% |
| Oct 31, 2018 | -1,385.04% |
| Jul 31, 2018 | 64.52% |
| Apr 30, 2018 | -170.08% |
| Jan 31, 2018 | -324.63% |
| Oct 31, 2017 | -197.34% |
| Jul 31, 2017 | -91.49% |
| Apr 30, 2017 | -332.23% |